Evaluating the Effect of Dexmedetomidine Infusion on Gene Expression of Inflammatory Cytokines & Lymphocyte T CD4 + Transcription Factors in Elective Abdominal Aortic Aneurysm Repair

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190121042444N1

Enrollment

Registered

2019-06-13

Start date

2018-07-23

Completion date

Unknown

Last updated

2019-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abdominal Aortic Aneurysm. -

Interventions

Intervention 1: The intervention group was subjected to anxiolytic infusion with doses of 0.3 mg / kg / hour doses of DEX until aortic clamp. Patients' blood samples were taken to determine the level

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with abdominal aortic aneurysms referring to Shohadaye Tajrish Hospital who are candidates for elective aneurysm repair surgery will be included in the study.

Exclusion criteria

Exclusion criteria: Previous history of aortic surgery ASA Class III and above IBD Malignancies Chronic inflammatory diseases Taking corticosteroids Emergency surgery Any unstable patient during surgery Any addiction

Design outcomes

Primary

Measure	Time frame
Relative level of mRNA; IL6. Timepoint: Before the beginning of the intervention (beginning of the study), the first day and the third day, and the time of discharge. Method of measurement: Sampling from patient's blood and filling in the questionnaire.;Relative level of mRNA; TNF-a. Timepoint: Before the beginning of the intervention (beginning of the study), the first day and the third day, and the time of discharge. Method of measurement: Sampling from patient's blood and filling in the questionnaire.;Relative level of Foxp3 mRNA. Timepoint: Before the beginning of the intervention (beginning of the study), the first day and the third day, and the time of discharge. Method of measurement: Sampling from patient's blood and filling in the questionnaire.;Relative level of GATA3mRNA. Timepoint: Before the beginning of the intervention (beginning of the study), the first day and the third day, and the time of discharge. Method of measurement: Sampling from patient's blood and filling in the questionnaire.;Relative level of IL-1mRNA. Timepoint: Before the beginning of the intervention (beginning of the study), the first day and the third day, and the time of discharge. Method of measurement: Sampling from patient's blood and filling in the questionnaire.;Relative level of ROR-. Timepoint: Before the beginning of the intervention (beginning of the study), the first day and the third day, and the time of discharge. Method of measurement: Sampling from patient's blood and filling in the questionnaire.;Relative level of T-bet mRNA. Timepoint: Before the beginning of the intervention (beginning of the study), the first day and the third day, and the time of discharg. Method of measurement: Sampling from patient's blood and filling in the questionnaire.	—

Measure

Time frame

Relative level of mRNA; IL6. Timepoint: Before the beginning of the intervention (beginning of the study), the first day and the third day, and the time of discharge. Method of measurement: Sampling from patient's blood and filling in the questionnaire.;Relative level of mRNA; TNF-a. Timepoint: Before the beginning of the intervention (beginning of the study), the first day and the third day, and the time of discharge. Method of measurement: Sampling from patient's blood and filling in the questionnaire.;Relative level of Foxp3 mRNA. Timepoint: Before the beginning of the intervention (beginning of the study), the first day and the third day, and the time of discharge. Method of measurement: Sampling from patient's blood and filling in the questionnaire.;Relative level of GATA3mRNA. Timepoint: Before the beginning of the intervention (beginning of the study), the first day and the third day, and the time of discharge. Method of measurement: Sampling from patient's blood and filling in the questionnaire.;Relative level of IL-1mRNA. Timepoint: Before the beginning of the intervention (beginning of the study), the first day and the third day, and the time of discharge. Method of measurement: Sampling from patient's blood and filling in the questionnaire.;Relative level of ROR-. Timepoint: Before the beginning of the intervention (beginning of the study), the first day and the third day, and the time of discharge. Method of measurement: Sampling from patient's blood and filling in the questionnaire.;Relative level of T-bet mRNA. Timepoint: Before the beginning of the intervention (beginning of the study), the first day and the third day, and the time of discharg. Method of measurement: Sampling from patient's blood and filling in the questionnaire.

—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactfaranak behnaz

Shahid Beheshti University of Medical Sciences

faranak.behnaz@gmail.com+98 21 2274 1174

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026